RxDoctor Payments Data

Gregory Phillips, MD

Family Medicine · Sibley, LANPI 1497743413

Payments from drug & device makers

$6,288in general payments, 2019–2025

Across 419 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$613
  • Amgen$594
  • GSK$395
  • Pfizer$374
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$6,19499%
  • Education$931%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,288 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$237,364
Medicare patients
530
Services billed
4,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide337$417,319
OzempicSemaglutide340$368,480
JardianceEmpagliflozin240$247,670
EliquisApixaban213$159,594
Trelegy ElliptaFluticasone/Umeclidin/Vilanter144$134,147
TrulicityDulaglutide75$92,639
RinvoqUpadacitinib12$75,631
Tresiba Flextouch U-200Insulin Degludec63$64,134
RybelsusSemaglutide30$50,150
EntrestoSacubitril/Valsartan65$47,304
LinzessLinaclotide46$41,912
VraylarCariprazine Hcl25$38,290
FarxigaDapagliflozin Propanediol49$37,575
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog44$30,031
XareltoRivaroxaban32$22,685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,002$509,958412 claims
Novo NordiskOzempic, Rybelsus$236$418,630370 claims
Boehringer IngelheimJardiance, Synjardy, Combivent Respimat, Tradjenta$146$291,491308 claims
PfizerEliquis$374$159,594213 claims
AbbVieRinvoq, Linzess, Vraylar$1,080$155,83383 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$395$155,604178 claims
NovartisEntresto$75$47,30465 claims
AstraZenecaFarxiga, Brilinta$613$46,57764 claims
MerckJanumet, Januvia$12$37,49354 claims
Johnson & JohnsonXarelto$112$22,68532 claims
Esperion Therapeutics, Inc.Nexletol$45$10,86314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Sibley

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →